Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Inovio Pharmaceuticals Q4 2023 GAAP EPS $(1.100) Beats $(1.270) Estimate, Sales $103.000K Miss $344.200K Estimate

Author: Benzinga Newsdesk | March 06, 2024 05:34pm
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(1.100) per share which beat the analyst consensus estimate of $(1.270) by 13.39 percent. The company reported quarterly sales of $103.000 thousand which missed the analyst consensus estimate of $344.200 thousand by 70.08 percent. This is a 17.60 percent decrease over sales of $125.000 thousand the same period last year.

Posted In: INO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist